Alpha Teknova, Inc. · NASDAQ:TKNO
Alpha Teknova — Investor Presentation (October 2026)
39 slides from Alpha Teknova's investor presentation, Oct 21, 2026
Slide 1: Making Solutions Possible: Company Overview
Exhibit 99.3 Making Solutions Possible COMPANY OVERVIEW October 2026
Slide 2: Forward-looking statements and use of non-GAAP financial measures
Forward-looking statements and use of non-GAAP financial measures This meeting is for the purpose of familiarizing you with Alpha Teknova, Inc. ( Teknova ) and is made for informational purposes only and nothing in the presentation should be viewed, or construed, as “advice”. You understand and agre
Slide 3: We Make Solutions Possible
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics 2026E REVENUE GROWTH PROJECT ADJUSTED 2026E REVENUE GUIDANCE (MIDPOINT) EBITDA POSITIVE QTR IN 14% 2027 $45-47M ACTIVE # CLINICAL CUSTOMER NUMBER
Slide 4: Our products are foundational to the life sciences industry
Our products are foundational to the life sciences industry LIQUID MICROBIAL MOLECULAR AGAR PLATES CULTURE MEDIA BIOLOGY REAGENTS AND SUPPLEMENTS Extensive selection of standard Wide variety of liquid media Vast range of product types, sizes, and specialty pre-poured agar and broths to expand a part
Slide 5: 2025 Revenue Breakdown
2025 REVENUE BREAKDOWN Primary End Markets 5% Non- Product Revenue APPROX. APPROX. APPROX. 400 1,900 1,000 ~15% ACCOUNTS ACCOUNTS ACCOUNTS Other Markets BIOPHARMA AND LIFE SCIENCE TOOLS OTHER MARKETS CONTRACT AND DIAGNOSTICS MANUFACTURING ~50% Biopharma & Contract ~30% • ~850 Biotech • ~250 Life Sci
Slide 6: Revenue by Product Type and Customer End Market
Revenue by Product Type and Customer End Market Total 2024 Revenue by OTHER Product Type and End Market 2025 REVENUE BREAKDOWN ~5% CLINICAL • Lab Essentials: ~75% of 2025 Revenue SOLUTIONS § Research-grade reagents (RUO) ~20% 15% § Catalog product revenue comprises ~80% CLINICAL SOLUTIONS Catalog §
Slide 7: Why We Win
Why We Win FASTER CATALOG BUSINESS SMALLER CUSTOM TURNAROUND TIME AS A FOUNDATION BATCH SIZES Initial Build Sizes for Custom Time from Order to Shipment Relative Annual Spend Research and Clinical Orders by Account Type in 2025 for Custom Orders 44X 10,000 L MONTHS 1,000 L Typical batch size for Eme
Slide 8: The barriers to producing similar custom reagents are considerable
The barriers to producing similar custom reagents for our target markets are considerable FACILITIES AND ESTABLISHED CO-LOCATED BESPOKE MODULAR INFRASTRUCTURE CATALOG BUSINESS MANUFACTURING SYSTEM Estimated Cost to Replicate: Estimated Time to Replicate: Estimated Time to Replicate: * * * $50M+, >3
Slide 9: Key Takeaways
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation ©
Slide 10: Continued success in attracting clinical customers
Continued success in attracting clinical customers 1 NUMBER OF CLINICAL SOLUTIONS CUSTOMERS 60 10 48 6 35 7 26 23 50 4 42 6 13 36% 28 2 22 17 2020-2025 11 CAGR 2020 2021 2022 2023 2024 2025 Biopharma Tools/Dx/Other Total 1 Customer is defined as any customer purchasing within the fiscal year. There
Slide 11: We are a critical supplier for more than therapies in clinical trials
We are a critical supplier for more than 70 therapies in clinical trials ~$3.0M ~$0.3M 29.8X ~$0.2M ~$0.1M 3.2X 1.4X 1X Illustrative Annual and Relative 1 Customer Spend by Phase CLINICAL DEVELOPMENT RESEARCH PRECLINICAL POST-APPROVAL AND DISCOVERY DEVELOPMENT PHASE Stage of Clinical Therapies Suppo
Slide 12: Life Science Tools and Diagnostics accounts comprise remaining Clinical Solutions customers
Life Science Tools and Diagnostics accounts comprise remaining Clinical Solutions customers These customers utilize Teknova to manufacture their proprietary formulations for resale or as raw materials in their manufacturing processes to support high growth end markets such as bioprocessing and liqui
Slide 13: Key Takeaways
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation ©
Slide 14: Supporting 3,000+ customers across the life sciences
Supporting 3,000+ customers across the life sciences Limited Customer Concentration Stable Top Accounts (Top Lab Essentials Revenue / Total Revenue) 2025 End Market Tenure 2019-25 CAGR Rank 1 Genomics >10 yrs 45% Top 5: 12% 42% 2 Genomics >10 yrs Top 10: 18% 72% 3 Genomics 9 yrs 4 Large Pharma >10 y
Slide 15: Our products are foundational to the life sciences industry
Our products are foundational to the life sciences industry Plasmid Production Gene DNA We support the leading life Synthesis and RNA science tools companies: • Sequencing • Single cell Spatial- Enzyme • Spatial genomics genomics Production • Enzyme production • Nucleic acid production Single- Seque
Slide 16: History of consistent double-digit growth
History of consistent double-digit growth LAB ESSENTIALS REVENUE $35,000,000 $30,000,000 $25,000,000 $20,000,000 $15,000,000 11% $10,000,000 2008-2025 $5,000,000 CAGR $- 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Pandemic © 2026 Alpha Teknova, Inc. ● Al
Slide 17: Key Takeaways
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation ©
Slide 18: Over $200M in revenue capacity with minimal additional capital
Over $200M in revenue * capacity with minimal additional capital investment required • ISO 13485-certified (GMP) facilities to support customers from discovery to commercialization 2 • Over 180,000 ft of facilities, including 2 approximately 10,000 ft of ISO 7 cleanrooms • In-house automation, engin
Slide 19: Effective cost management sets up attractive financial profile
FTEs (#) Effective cost management after period of investment sets up attractive financial profile with top-line growth $45 300 $41 $41 $35 $38 $37 250 $25 200 $15 ADJUSTED EBITDA 150 POSITIVE QTR $5 BEFORE THE END OF 100 ($7) ($5) ($15) 50 ($15) ($20) 2027 ($22) ($25) 0 2022 2023 2024 2025 Revenue
Slide 20: Significant operating leverage with top-line growth
SIGNIFICANT OPERATING LEVERAGE WITH TOP-LINE GROWTH 70% of revenue growth drops to bottom line 65%+ Gross Margin Gross Profit Variable Cost of Goods Sold • Grows in proportion to revenue – direct materials, packaging, scrap/waste, supplies, etc. • ~25-30% of total cost of sales today 55-60% Gross Ma
Slide 21: Key Takeaways
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation ©
Slide 22: Near-term catalyst: Investing in commercial capabilities
NEAR-TERM CATALYST Investing in commercial capabilities and activities INVESTMENT ($2M) SITUATION 1. Expand field team with expertise in life science • We believe that Biopharma end markets have stabilized and tools, diagnostics, and large pharma higher funding levels will persist 2. Drive more bran
Slide 23: New AI-Powered Assistant: Build-Tek Custom Configurator
NEW AI-POWERED ASSISTANT TM Build●Tek Custom Configurator Build complex custom product requests in minutes with Teknova’s interactive reagent assistant 3 minutes 3 days 30 years Build a complete Submit your Proven custom custom order with configuration and our reagent manufacturing just a few clicks
Slide 24: New Manufacturing Capability: Fill-Tek Dispensing System
NEW MANUFACTURING CAPABILITY TM Fill●Tek Dispensing System Increased customer demand for multiple bag sizes and filling configurations from the same production run led the team to develop our new single-use bag filling process • Provides greater flexibility for more varied custom GMP orders § Remove
Slide 25: Near-term catalyst: four-quarter lag between funding and revenue
NEAR-TERM CATALYST Historically seen a four-quarter lag between funding changes and effects on revenue 45 6 4-QUARTER 40 SHIFT SITUATION 5 35 • Biotech funding has been mostly down since mid-2022 30 4 • Substantial rebound in funding 25 observed starting in Q4:2025 3 • Strong first half growth in 20
Slide 26: Near-term catalyst: Opportunity to expand through tuck-in M&A
NEAR-TERM CATALYST Opportunity to expand through tuck-in M&A Specific areas of interest: • Cell culture media and supplements • Transfection reagents • Cytokines, growth factors, enzymes, antibodies and other proteins • Geographic expansion © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October
Slide 27: Proven management team with extensive experience in life sciences
Proven management team with extensive experience in life sciences Stephen Gunstream Matt Lowell Jennifer Henry Damon Terrill President & Chief Executive Officer Chief Financial Officer Senior Vice President, General Counsel, Marketing Chief Compliance Officer Bella Neufeld Shari Hubbell Neil Abhyank
Slide 28: Leading provider of custom research and GMP-grade reagents
Leading provider of custom research and GMP-grade reagents ready to support our customers as they scale We are successfully executing on our long-term growth plan, having increased our Clinical Solutions customer 1 base from 13 to 60 over the past five years We believe we are poised to drive signifi
Slide 29: Q2:26 Financials
-_ _ Q2:26 Financials
Slide 30: Q2:2026 Revenue Highlights
Q2:2026 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $12.2 • Total second quarter revenue up 18% compared to the same period in $10.3 18% y/y $2.4 prior year • Lab Essentials increased 18% $2.1 compared to the same period in prior year • Clinical Solutions increased 18% $9.2 compared t
Slide 31: Q2:2026 Income Statement Highlights
Q2:2026 Income Statement Highlights Gross Margin (%) Total OpEx ($M) $7.8 $7.4 40.1% 38.7% Q2:2025 Q2:2026 Q2:2025 Q2:2026 1 Diluted EPS ($) Adjusted EBITDA ($M) ($0.7) ($0.06) ($0.8) ($0.07) Q2:2025 Q2:2026 Q2:2025 Q2:2026 1 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any
Slide 32: Q2:2026 Cash Flow and Balance Sheet Highlights
Q2:2026 Cash Flow and Balance Sheet Highlights 1 Capital Expenditure ($M) Free Cash Flow ($M) ($0.6) ($2.3) $0.2 $0.1 Q2:2025 Q2:2026 Q2:2025 Q2:2026 Cash, Cash Equivalents, and Short-Term Investment was $17.4M as of June 30, 2026 1 Free Cash Flow equals cash provided by (used in) operating activiti
Slide 33: Quarterly Financial Trends
Quarterly Financial Trends 1 Gross Margin (%) Total OpEx ($M) $10.2 $8.0 $8.1 $7.9 $7.9 $7.8 $7.8 $7.5 $7.4 $7.2 40% 39% 34% 32% 31% 31% 30% 29% $8.9 $8.1 $8.0 $7.8 $7.8 $7.8 $7.5 $7.4 $7.4 24% $7.2 23% Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q
Slide 34: 2026 Outlook and Capital Runway
2026 Outlook and Capital Runway GUIDANCE • Raising fiscal 2026 outlook for revenue and improving outlook for Free Cash Outflow • Anticipate total revenue of $45 million to $47 million for fiscal year ending December 31, 2026 (“2026”), up 14% y/y at the midpoint • Targeting Free Cash Outflow of less
Slide 35: Preliminary Q3:26 Financials
Preliminary Q3:26 Financials
Slide 36: Preliminary Q3:26 Financial Results
Preliminary Q3:26 Financial Results Q3 Highlights Metric Expected Result • Total revenue up 19% to 21% compared to the same period prior year Revenue $12.5M – $12.7M § Clinical Solutions revenue grew high double digits compared to the same period prior year, marking the highest revenue in over 3 yea
Slide 37: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 38: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 38
Slide 39: Teknova
teknova: